There is provided herein a composition for boosting the immune system comprising a keratin compound and beta-lactoglobulin (LGB).

The present invention has an object providing microparticles having an average particle size of 100 μm or less.

The present invention provides microparticles having an average particle size of 100 μm or less and a method for producing thereof. In addition, the present invention provides medicine, food and feedstuff comprising the microparticles having an average particle size of 100 μm or less.

The present invention has an object providing microparticles having an average particle size of 100 μm or less.

The present invention provides microparticles having an average particle size of 100 μm or less and a method for producing thereof. In addition, the present invention provides medicine, food and feedstuff comprising the microparticles having an average particle size of 100 μm or less.

The present disclosure provides methods of treating plasma protein imbalances or depletion (e.g., plasma protein imbalances or depletion caused by hemorrhagic shock or other clinical conditions), in particular by administering protein compositions derived from plasma or plasma isolates.

The present disclosure provides methods of treating plasma protein imbalances or depletion (e.g., plasma protein imbalances or depletion caused by hemorrhagic shock or other clinical conditions), in particular by administering protein compositions derived from plasma or plasma isolates.

The present disclosure provides methods of treating plasma protein imbalances or depletion (e.g., plasma protein imbalances or depletion caused by hemorrhagic shock or other clinical conditions), in particular by administering protein compositions derived from plasma or plasma isolates.

The present invention relates to methods and immunonutritional compositions for preventing or mitigating paralysis of the bone marrow, caused by a tumor or neoplasm, between cycles of and after anti-cancer therapy, thereby attaining a better efficacy of the treatment. More particularly, the present invention relates to methods and immunonutritional compositions that can transiently preventing or moderating, bone marrow paralysis or neutropenia of a subject tumor-induced apoptosis or necrosis or other cell damage such that the innate and adaptive immune functions and normal physiology of the bone marrow are preserved, at least in part, which, in turn, lead to (i) a better tolerance and increased efficacy to treatment; (ii) transient augmentation or enhancement of immunocompetence of the immune cell; and (iii) optimization of the effects of and increase of immunocompetence of the immune cell weakened due to paralysis of the bone marrow, caused by a tumor or neoplasm.

The present invention relates to methods and immunonutritional compositions for preventing or mitigating paralysis of the bone marrow, caused by a tumor or neoplasm, between cycles of and after anti-cancer therapy, thereby attaining a better efficacy of the treatment. More particularly, the present invention relates to methods and immunonutritional compositions that can transiently preventing or moderating, bone marrow paralysis or neutropenia of a subject tumor-induced apoptosis or necrosis or other cell damage such that the innate and adaptive immune functions and normal physiology of the bone marrow are preserved, at least in part, which, in turn, lead to (i) a better tolerance and increased efficacy to treatment; (ii) transient augmentation or enhancement of immunocompetence of the immune cell; and (iii) optimization of the effects of and increase of immunocompetence of the immune cell weakened due to paralysis of the bone marrow, caused by a tumor or neoplasm.

A synthetic nutritional composition comprising: ruminant milk fat wherein the milk fat is capable of activating the aryl hydrocarbon receptor (AhR) in an AhR activity assay; and a ruminant immunoglobulin.

A synthetic nutritional composition comprising: ruminant milk fat wherein the milk fat is capable of activating the aryl hydrocarbon receptor (AhR) in an AhR activity assay; and a ruminant immunoglobulin.